 COA |
MSDS |
 HPLC |
NMR |
| CAS No: | 1418033-25-6 |
| Molecular formula(MF) | C15H22N2O4 |
| Molecular Weight(MW): | 294.35 |
| Alias |
| In vitro | DMSO | 58 mg/mL (197.04 mM) |
|---|---|---|
| Ethanol | 58 mg/mL (197.04 mM) | |
| Water | <1 mg/mL | |
| In vivo |
| Description | LMK-235 is a selective inhibitor of HDAC4 and HDAC5 with IC50 of 11.9 nM and 4.2 nM, respectively. | ||||
|---|---|---|---|---|---|
| Targets |
|
||||
| In vitro |
LMK-235 causes HDAC inhibition with IC50 of <1 μM in human cancer cell lines with different sensitivity towards cisplatin. In breast cancer cell line MDA-MB-231, tongue cancer cell line Cal27, and esophagus cell line Kyse510 cell line, LMK-235 displays a high cytotoxicity, and markedly enhances the cytotoxicity of cisplatin. [1] In addition, LMK-235 also shows nanomolar activity against multiple malaria parasite life cycle stages. [2] |